• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.作为用于治疗精神疾病或中枢神经系统疾病的5-HT2A激动剂的新型化合物。
ACS Med Chem Lett. 2025 Feb 11;16(3):377-378. doi: 10.1021/acsmedchemlett.5c00066. eCollection 2025 Mar 13.
2
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.新型色胺化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
3
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
4
Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses.作为用于治疗精神疾病的5-HT2A激动剂的新型吡咯并吡啶化合物。
ACS Med Chem Lett. 2025 Jan 23;16(2):202-203. doi: 10.1021/acsmedchemlett.5c00019. eCollection 2025 Feb 13.
5
Novel Pyridine Derivatives as 5-HT2A Agonists for Treating Psychiatric Disorders.新型吡啶衍生物作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 Jan 8;16(2):192-193. doi: 10.1021/acsmedchemlett.4c00629. eCollection 2025 Feb 13.
6
Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders.新型麦角灵类化合物作为5-羟色胺2A受体激动剂用于治疗情绪障碍
ACS Med Chem Lett. 2025 May 21;16(6):974-975. doi: 10.1021/acsmedchemlett.5c00288. eCollection 2025 Jun 12.
7
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric Disorders.新型苯基烷基胺作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 May 14;16(6):948-949. doi: 10.1021/acsmedchemlett.5c00269. eCollection 2025 Jun 12.
8
Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.新型3-环氨基吲哚化合物作为用于治疗精神病、精神疾病和中枢神经系统疾病的5-羟色胺能致幻剂。
ACS Med Chem Lett. 2025 Jan 4;16(2):190-191. doi: 10.1021/acsmedchemlett.4c00615. eCollection 2025 Feb 13.
9
Novel Pyridine Derivatives as 5‑HT2A Agonists for Treating Psychiatric Disorders.新型吡啶衍生物作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 May 13;16(6):929-930. doi: 10.1021/acsmedchemlett.5c00244. eCollection 2025 Jun 12.
10
Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain Disorders.新型异色胺四环类化合物作为5-HT2A激动剂用于治疗脑部疾病。
ACS Med Chem Lett. 2025 May 9;16(6):933-934. doi: 10.1021/acsmedchemlett.5c00246. eCollection 2025 Jun 12.

引用本文的文献

1
Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.新型吲哚衍生物作为用于治疗精神病、精神疾病和中枢神经系统疾病的血清素能致幻剂。
ACS Med Chem Lett. 2025 May 30;16(6):982-983. doi: 10.1021/acsmedchemlett.5c00309. eCollection 2025 Jun 12.

本文引用的文献

1
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.新型3-吡咯烷吲哚衍生物作为5-羟色胺能致幻剂用于治疗精神病以及抑郁症和创伤后应激障碍等精神疾病。
ACS Med Chem Lett. 2024 Dec 10;16(1):18-19. doi: 10.1021/acsmedchemlett.4c00581. eCollection 2025 Jan 9.
2
Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature.前扣带回皮层中5HT2A受体激活的抗抑郁和抗焦虑作用及其潜在理论机制——现有文献的综述
Brain Res. 2025 Jan 1;1846:149226. doi: 10.1016/j.brainres.2024.149226. Epub 2024 Sep 7.
3
1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review.1-（2,5-二甲氧基-4-碘苯基）-2-氨基丙烷（DOI）：从一种鲜为人知的物质到血清素致幻剂DOX家族的关键成员——综述
ACS Pharmacol Transl Sci. 2024 May 8;7(6):1722-1745. doi: 10.1021/acsptsci.4c00157. eCollection 2024 Jun 14.
4
Psychedelic therapy in depression and substance use disorders.致幻剂治疗抑郁症和物质使用障碍。
Eur J Neurosci. 2024 Jul;60(2):4063-4077. doi: 10.1111/ejn.16421. Epub 2024 May 21.
5
The role of serotonin in depression-A historical roundup and future directions.血清素在抑郁症中的作用——历史综述及未来方向
J Neurochem. 2024 Sep;168(9):1751-1779. doi: 10.1111/jnc.16097. Epub 2024 Mar 13.
6
Serotonin 2A Receptor (5-HTR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.血清素2A受体（5-羟色胺受体）激动剂：作为新型抗抑郁药的致幻剂和非致幻类似物
Chem Rev. 2024 Jan 10;124(1):124-163. doi: 10.1021/acs.chemrev.3c00375. Epub 2023 Nov 30.

作为用于治疗精神疾病或中枢神经系统疾病的5-HT2A激动剂的新型化合物。

Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.

作者信息

Sabnis Ram W, Sabnis Anika R

机构信息

Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.

Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.

出版信息

ACS Med Chem Lett. 2025 Feb 11;16(3):377-378. doi: 10.1021/acsmedchemlett.5c00066. eCollection 2025 Mar 13.

DOI:10.1021/acsmedchemlett.5c00066
PMID:40104807
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11912257/
Abstract

Provided herein are novel compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mental illness or CNS disorders and processes for preparing such compounds.

摘要

本文提供了作为5-羟色胺2A（5-HT2A）激动剂的新型化合物、药物组合物、此类化合物在治疗精神疾病或中枢神经系统（CNS）疾病中的用途以及制备此类化合物的方法。